The CHOICE Registry
NCT03148093 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2024-09-04
Summary
The CHOICE Registry will describe real-world treatment patterns and physician and patient (and caregiver)-reported outcomes associated with patients who have progressed beyond 2nd line metastatic colorectal cancer.
Conditions
Sponsors & Collaborators
-
Taiho Oncology, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-06-30
- Primary Completion
- 2017-10-20
- Completion
- 2017-12-13
Countries
- United States
Study Locations
More Related Trials
-
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
NCT00557102 ·Status: COMPLETED ·Phase: PHASE2
-
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02368886 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
NCT00230399 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
NCT00975897 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer
NCT06858969 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354 ·Status: COMPLETED ·Phase: PHASE2
-
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
NCT01607957 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
NCT05513742 ·Status: COMPLETED ·Phase: PHASE2
-
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00005981 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
NCT01729923 ·Status: TERMINATED ·Phase: PHASE2
-
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen
NCT00250029 ·Status: COMPLETED ·Phase: NA
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
NCT06412198 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
NCT02835924 ·Status: COMPLETED ·Phase: PHASE2
-
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
NCT06575725 ·Status: WITHDRAWN ·Phase: PHASE2
-
xDRIVE in Metastatic Colorectal Cancer
NCT06929338 ·Status: NOT_YET_RECRUITING
-
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
NCT02316496 ·Status: TERMINATED ·Phase: PHASE2
-
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
NCT03599752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
NCT00835679 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
NCT06678919 ·Status: RECRUITING
-
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
NCT03031691 ·Status: COMPLETED ·Phase: PHASE1
-
Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials
NCT03350412 ·Status: UNKNOWN
-
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
NCT00642746 ·Status: TERMINATED ·Phase: PHASE2
-
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
NCT05970705 ·Status: RECRUITING ·Phase: PHASE2
-
Sacituzumab Govitecan in Metastatic Colorectal Cancer
NCT06243393 ·Status: RECRUITING ·Phase: PHASE2/PHASE3